Demographics and clinical characteristics at diagnosis and before CAR T-cell therapy
| Characteristic . | Total cohort (n = 96) . |
|---|---|
| Median age, y (range) | 56 (18-79) |
| Sex, n (%) | |
| Male | 65 (67.7) |
| Lymphoma histology, n (%) | |
| DLBCL | 51 (53.1) |
| Transformed lymphoma | 20 (20.8) |
| HGBL | 9 (9.4) |
| PMBCL | 8 (8.3) |
| THRLBCL | 6 (6.2) |
| Nontransformed follicular lymphoma | 2 (2.1) |
| Cell of origin, n (%) | |
| GCB | 39 (55.6) |
| Non-GCB | 31 (44.3) |
| Missing/unknown | 26 |
| DEL, n (%) | |
| Yes | 28 (45.2) |
| No | 34 (54.8) |
| Missing/unknown | 34 |
| DHL, n (%) | |
| Yes | 16 (22.2) |
| No | 56 (77.8) |
| Missing/unknown | 24 |
| ECOG PS, n (%) | |
| 0 | 32 (40.5) |
| 1 | 36 (45.6) |
| 2 | 10 (12.7) |
| 3 | 1 (1.3) |
| Missing/unknown | 17 |
| Ann-Arbor stage, n (%) | |
| I | 2 (2.2) |
| II | 14 (15.1) |
| III | 22 (23.7) |
| IV | 55 (59.1) |
| Missing/unknown | 3 |
| B symptoms, n (%) | |
| Yes | 38 (46.9) |
| No | 43 (53.1) |
| Missing/unknown | 15 |
| Extranodal disease, n (%) | |
| No | 28 (30.4) |
| Yes, only 1 site | 38 (41.3) |
| Yes, >1 site | 26 (28.3) |
| Missing/unknown | 4 |
| LDH > upper limit of normal, n (%) | |
| Yes | 51 (75.0) |
| No | 17 (25.0) |
| Missing/unknown | 28 |
| CNS involvement present at diagnosis, n (%) | |
| Yes | 6 (6.5) |
| No | 87 (93.5) |
| Missing/unknown | 3 |
| R-IPI score, n (%) | |
| 1 | 18 (25.4) |
| 2 | 17 (23.9) |
| 3 | 23 (32.4) |
| 4 | 11 (15.5) |
| 5 | 2 (2.8) |
| Missing/unknown | 25 |
| Treatment received before CAR-T | |
| Median lines of therapy before CAR-T, n (range) | 3 (1-10) |
| Primary refractory disease, n (%) | 48 (50) |
| Previous radiation therapy, n (%) | 35 (36.5) |
| Previous transplant, n (%) | 26 (27.1) |
| Previous immunomodulatory agent therapy, n (%) | 16 (16.7) |
| Previous BTK inhibitor therapy, n (%) | 11 (11.5) |
| Previous CPI therapy, n (%) | 7 (7.3) |
| Characteristic . | Total cohort (n = 96) . |
|---|---|
| Median age, y (range) | 56 (18-79) |
| Sex, n (%) | |
| Male | 65 (67.7) |
| Lymphoma histology, n (%) | |
| DLBCL | 51 (53.1) |
| Transformed lymphoma | 20 (20.8) |
| HGBL | 9 (9.4) |
| PMBCL | 8 (8.3) |
| THRLBCL | 6 (6.2) |
| Nontransformed follicular lymphoma | 2 (2.1) |
| Cell of origin, n (%) | |
| GCB | 39 (55.6) |
| Non-GCB | 31 (44.3) |
| Missing/unknown | 26 |
| DEL, n (%) | |
| Yes | 28 (45.2) |
| No | 34 (54.8) |
| Missing/unknown | 34 |
| DHL, n (%) | |
| Yes | 16 (22.2) |
| No | 56 (77.8) |
| Missing/unknown | 24 |
| ECOG PS, n (%) | |
| 0 | 32 (40.5) |
| 1 | 36 (45.6) |
| 2 | 10 (12.7) |
| 3 | 1 (1.3) |
| Missing/unknown | 17 |
| Ann-Arbor stage, n (%) | |
| I | 2 (2.2) |
| II | 14 (15.1) |
| III | 22 (23.7) |
| IV | 55 (59.1) |
| Missing/unknown | 3 |
| B symptoms, n (%) | |
| Yes | 38 (46.9) |
| No | 43 (53.1) |
| Missing/unknown | 15 |
| Extranodal disease, n (%) | |
| No | 28 (30.4) |
| Yes, only 1 site | 38 (41.3) |
| Yes, >1 site | 26 (28.3) |
| Missing/unknown | 4 |
| LDH > upper limit of normal, n (%) | |
| Yes | 51 (75.0) |
| No | 17 (25.0) |
| Missing/unknown | 28 |
| CNS involvement present at diagnosis, n (%) | |
| Yes | 6 (6.5) |
| No | 87 (93.5) |
| Missing/unknown | 3 |
| R-IPI score, n (%) | |
| 1 | 18 (25.4) |
| 2 | 17 (23.9) |
| 3 | 23 (32.4) |
| 4 | 11 (15.5) |
| 5 | 2 (2.8) |
| Missing/unknown | 25 |
| Treatment received before CAR-T | |
| Median lines of therapy before CAR-T, n (range) | 3 (1-10) |
| Primary refractory disease, n (%) | 48 (50) |
| Previous radiation therapy, n (%) | 35 (36.5) |
| Previous transplant, n (%) | 26 (27.1) |
| Previous immunomodulatory agent therapy, n (%) | 16 (16.7) |
| Previous BTK inhibitor therapy, n (%) | 11 (11.5) |
| Previous CPI therapy, n (%) | 7 (7.3) |
BTK, Bruton’s tyrosine kinase; GCB, germinal center B-cell; R-IPI, Revised International Prognostic Index.